IFN-α potentiates a distinct anti-tumor immune mechanism from anti-PD-L1 blockade and may explain why anti-PD-L1-IFN-α fusion can overcome the anti-PD-L1 resistance in the mouse model. The gene discussed is IFNA1; the disease is neoplasm.